Trial Profile
Comparison of the effect of Yasmin and Cyproteron compound on metabolic syndrome in women with confirmed polycystic ovary syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Sep 2016
Price :
$35
*
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary) ; Ethinylestradiol/cyproterone (Primary)
- Indications Metabolic syndrome; Polycystic ovary syndrome
- Focus Therapeutic Use
- 08 Feb 2013 Recruitment complete, according to the Iranian Registry of Clinical Trials.
- 12 Jul 2012 New trial record